Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study

The ELBA Study showed an evolving landscape in biomarker-driven and molecular targeted therapies in early-stage NSCLC management towards the integration of mutational testing into clinical practice, with a growing focus on an optimal definition of adjuvant treatment.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-02-16
DOI
https://doi.org/10.3389/fonc.2026.1724019
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study

Iacopo Fioroni, Monica Gesualdo, Paola Muscolino, E Mazzotti et al.
Frontiers in Oncology
Lung Cancer Treatments and Mutations
article

Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study

Iacopo Fioroni, Monica Gesualdo, Paola Muscolino, E Mazzotti, Lucia Bonomi, Valerio Gristina, Raffaele Giusti, Vincenzo Gennusa, A. Catino, Ivana Caprice, I. Vallini, Ilaria Furfaro, Barbara Roncari, Elio Gregory Pizzutilo, A. Russo, Salvatore Intagliata, Lucia Simoni, F. Mazzoni, Stefano Stabile, Alessandra Bulotta, Francesca Rita Ogliari, Francesco Jacopo Romano, Michele Ferrara, M. Nuzzo, Elena Tosoni, Marta Brambilla, Giuseppe Viscardi, Francesca Zepponi, Maria Grazia Viganò, Anna Zanetti, Giusy Parisi, Mattia Banfi, Sara Oresti, Valentina Bohórquez Polo, C Genova, Linda Zinoli, Giovanna Marrapese, Sabrina Mariotti, Viola Cutifani, Francesca Sperandi, Lorenzo Belluomini, Anna Bettini, Alessandro Scala, Cristiano Serci, Giulia Marcantognini, Giulia Pasello, Alberto Pavan, Roberto Vigano, Carmine D’Aniello, Giulia Barletta, Giuseppe Pasqualetti, Rosa Maria Di Mauro, Stefano Zanini, Alessia Longo, Alice Lunghi, Manuela Otero, Marco Sposito, Nicola Fogale, Susanna Yedro, Elisa Roca, Rita Chiari, Sara Pilotto, Andrea De Giglio, Claudia Proto, Roberto Ginesi, Antonietta Guida, Rosaria Laudiero, Lorenzo Antonuzzo, Emilio Bria, Laura Ghilardi, Veronica Franchina, Silvia Moroni, Alessandro Contaldi, Editta Baldini, Alice Bardocci, Claudia Fusco, Silvia Bianco, Vincenzo Montesarchio, Francesca Martinelli, Francesco Gelsomino, Serena Cosentino, Davide Mannini, Giorgio Madonia, Raffaella Stefania Siesto Andrea Planeta, Jessica Insolda, Teresa Ginesi, Vanessa Ruzzarin, Vittoria Iorio, Maria Caterina Russo, Eleonora Valli, Valentina Marino, Arianna Fabbri, Federico Cappuzzo, Mirella Moro, Alessandra Carbone
article en

Abstract

The ELBA Study showed an evolving landscape in biomarker-driven and molecular targeted therapies in early-stage NSCLC management towards the integration of mutational testing into clinical practice, with a growing focus on an optimal definition of adjuvant treatment.

Frontiers in OncologyVol. 16
University of Insubria (IT), University of Verona (IT), AOL (United States) (US), University of Padua (IT), Vita-Salute San Raffaele University (IT), Agostino Gemelli University Polyclinic (IT), IQVIA (United Kingdom) (GB), Ospedale Antonio Cardarelli (IT), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), San Salvatore Hospital (IT), Ospedale Papa Giovanni XXIII (IT), Istituto Oncologico Veneto (IT), Azienda Ospedaliero-Universitaria Careggi (IT), Azienda USL di Bologna (IT), Azienda Ospedaliera Sant'Andrea (IT), German Center for Lung Research (DE), Istituto Tumori Bari (IT), IRCCS Ospedale San Raffaele (IT), National Cancer Institute (MY), Policlinico Tor Vergata (IT), AstraZeneca (Italy) (IT), Ospedale Monaldi (IT), Campus Bio Medico University Hospital (IT), Ospedale dell' Angelo (IT), Tumori Foundation (US), Ca' Foncello Hospital (IT), Ospedale Policlinico San Martino (IT), IQ Solutions (US), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte (IT), University of Milano-Bicocca (IT)
Openalex Percentile: Top 54%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.